2025-11793RuleWallet

FDA Gives Specialized Cancer-Test Technology a New Regulatory Lane

Published Date: 6/26/2025

Rule

Summary

The FDA is officially classifying a special test that spots chromosome problems in blood cancer patients as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the test is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on June 26, 2025, and could save time and money for companies making these tests.

Analyzed Economic Effects

4 provisions identified: 2 benefits, 1 costs, 1 mixed.

Class II classification speeds patient access

The FDA officially classified fluorescence in situ hybridization (FISH) tests for chromosomal abnormalities in hematologic malignancies as Class II (special controls) effective June 26, 2025 (classification applicable December 21, 2018). The Agency says this classification provides reasonable assurance of safety and effectiveness and will enhance patients' access to innovative tests by reducing regulatory burdens.

New predicate enables easier 510(k) pathway

Because FDA classified this FISH test via the De Novo process, the device can serve as a predicate for future devices of the same type, allowing other sponsors to use the less-burdensome 510(k) premarket notification process rather than a premarket approval (PMA). This change is described as reducing regulatory burdens for future device sponsors.

Manufacturers must meet detailed validation rules

Manufacturers must meet Class II special controls including detailed design verification and validation. Explicit requirements include: analytical sensitivity data with a minimum of 25 specimens from karyotypically normal males; analytical specificity data with a minimum of 5 such specimens; precision/reproducibility with at least 6 clinical specimens (2 negative, 2 near cut-off, 2 positive) tested across 3 sites with 2 operators each over 3–5 non-consecutive days and each specimen run in duplicate for a minimum of 30 replicates; between-reagent lot reproducibility with 3 reagent lots and 3 clinical specimens; and multiple stability studies.

Labeling and lab responsibilities required

Labeling must state: "The test is not intended for use as a stand-alone diagnostic, disease screening, or as a companion diagnostic." The labeling must show performance study results and acceptance criteria, and must include limiting statements that results be interpreted by a qualified pathologist or cytogeneticist. Each laboratory is responsible for establishing its own cut-off values and should test a sufficiently large number of samples to assign a cut-off.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
6/26/2025
6/26/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register